Item 4.01 Changes in Registrant’s Certifying Accountant.
Effective July 15, 2021, AcelRx Pharmaceuticals, Inc.’s (the “Company”) independent registered public accounting firm, OUM & Co., LLP (“OUM”), combined its business (the “Acquisition”) with WithumSmith+Brown, PC (“Withum”). As a result of the Acquisition, on July 29, 2021, OUM resigned as the Company's independent registered public accounting firm. Concurrently with such resignation, the Company, with the approval of the Audit Committee of the Company’s Board of Directors, consented to the assignment of OUM’s engagement (the “Engagement”) with the Company to, and its assumption by, Withum. Withum became the Company’s independent registered public accounting firm upon its assumption of the Engagement on July 29, 2021.
The reports of OUM on the consolidated financial statements of the Company for the years ended December 31, 2020 and 2019 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principle. In connection with its audits of the years ended December 31, 2020 and 2019 and reviews of the Company's consolidated financial statements through the date of this report, there were no disagreements with OUM on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of OUM, would have caused it to make reference thereto in their report on the consolidated financial statements for such years.
The Company has furnished to OUM the statements made in this Item 4.01. Attached as Exhibit 16.1 to this Form 8-K is OUM’s letter to the Commission, dated July 29, 2021 regarding these statements.
During the two most recent fiscal years and through the date of this report, the Company has not consulted with Withum on any matter that (i) involved the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's consolidated financial statements, in each case where a written report was provided or oral advice was provided that Withum concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) was either the subject of a disagreement, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
Description
|
16.1
|
Letter
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|